SCHEMBL622929

SCHEMBL622929

CC(=O)Nc1cc(-c2cc(-c3nnc[nH]3)c(N3CCCC(N(C)C)C3)o2)c(C)cn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
CDC42BPA Q5VT25 1/20 0.34
CDC42BPB Q9Y5S2 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1F P30939 1/20 0.33
CDK9 P50750 5/20 0.33
PIK3CG P48736 1/20 0.32
GSK3B P49841 5/20 0.32
DYRK1A Q13627 5/20 0.32
BUB1 O43683 1/20 0.31
CCNT1 O60563 4/20 0.31
CDK4 P11802 3/20 0.31
CCND1 P24385 3/20 0.31
LCK P06239 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9108495 0.83 PIK3C3 (0.35) ROCK2ROCK1CDC42BPACDC42BPBPIK3C3
SCHEMBL9890604 0.79 PIK3C3 (0.45) PIK3C3HTR1AHTR1DHTR1F
SCHEMBL624381 0.77 CSNK2A2 (0.31) CSNK2A2CSNK2BCSNK2A1CDK9CCNT1
SCHEMBL9889941 0.71 PIK3C3 (0.36) PIK3C3GSK3BJAK1
SCHEMBL9104256 0.70 PIK3C3 (0.40) PIK3C3CSNK2A2CSNK2BCDK4CCND1
SCHEMBL9108830 0.70 KDM4E (0.36) PIK3C3
SCHEMBL9890493 0.70 WDR5 (0.36) CDK9GSK3BDYRK1AWNT1
SCHEMBL9888610 0.69 S1PR4 (0.38) PIK3C3
SCHEMBL10183413 0.67 CSNK2A2 (0.33) ROCK2ROCK1CDC42BPACDC42BPBPIK3C3
SCHEMBL15050952 0.65 PIK3C3 (0.42) PIK3C3HTR1AHTR1DHTR1FCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
US-8859768-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-10-14 US disclosed
EP-2603216-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2013-06-19 EP disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
US-20120142732-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-06-07 US disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed
WO-2012021615-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142732-A1 HETEROARYLS AND USES THEREOF PIK3R4, PIK3C2B, PIK3R1 ROCK2 591/4885ROCK1 273/4885CDC42BPA 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.